肽是一类非常关键的药物化合物，可以控制多种信号传导途径，从而影响许多生理和生化过程。先前的研究表明，肽和抗体都可以作为跨不同领域的研究、诊断、疫苗接种和治疗的有效工具。肽的独特属性，例如其深刻的组织渗透性、有效的细胞内化、降低的免疫原性以及对化学修饰的适应性，强调了它们在生物医学应用中的重要性。然而，它们也具有亲和力低、吸收差、蛋白水解稳定性低、清除快等缺点。肽体的出现是一项重大进步，改善了肽和抗体的局限性。肽体或肽-Fc 融合体代表了一种有前途的治疗方式，包含与 Fc 结构域融合的生物活性肽。这种融合策略增强了肽的稳定性和功效，克服了一些固有的局限性。许多肽体已被开发用于治疗癌症、糖尿病和狼疮等疾病。 Romiplostim 和 Dulaglutide 是唯一分别获得 EMA 和 FDA 批准的药物。鉴于肽体在制药领域的重要性日益增强，本研究旨在解释肽的内在特性、肽体生产的复杂性及其潜在的治疗应用等关键方面。版权所有 © 2024。由 Elsevier B.V. 出版。

Peptides are a very critical class of pharmaceutical compounds that can control several signaling pathways and thereby affect many physiological and biochemical processes. Previous research suggests that both peptides and antibodies may serve as potent tools for research, diagnostics, vaccination, and therapeutics across diverse domains. The distinct attributes of peptides, like their profound tissue penetration, efficient cellular internalization, reduced immunogenicity, and adaptability to chemical modification, underscore their significance in biomedical applications. However, they also possess drawbacks such as lower affinity, poor absorption, low stability to proteolytic digestion, and rapid clearance. The advent of peptibodies is a significant advance that improves the limitations of both peptides and antibodies. Peptibodies, or Peptide-Fc fusions, represent a promising therapeutic modality comprising biologically active peptides fused to an Fc domain. The stability and efficacy of the peptide are enhanced by this fusion strategy, which overcomes some of the inherent limitations. Many peptibodies have been developed to treat conditions like cancer, diabetes, and lupus. Romiplostim and Dulaglutide are the only ones approved by the EMA and FDA, respectively. Given the growing significance of peptibodies in the pharmaceutical landscape, this investigation aims to explain key aspects encompassing the intrinsic properties of peptides, the intricacies of peptibody production, and their potential therapeutic applications.Copyright © 2024. Published by Elsevier B.V.